Tony Mok

Tony Mok led the landmark IPASS trial demonstrating superior progression-free survival with gefitinib over carboplatin plus paclitaxel in EGFR-mutated advanced NSCLC in Asian patients, fundamentally establishing EGFR tyrosine kinase inhibitors as first-line therapy for this biomarker-selected population. His research has characterized the epidemiology of EGFR mutations in Asian NSCLC, where rates of 50-60% in adenocarcinoma significantly exceed Western populations, and examined how EGFR mutation subtypes predict differential responses across TKI generations. He has contributed to clinical development of osimertinib including the AURA and FLAURA trials, and investigation of combination strategies including osimertinib plus ramucirumab and datopotamab deruxtecan for EGFR-mutated NSCLC. His contributions to Asian oncology clinical trial networks have been foundational for conducting high-quality trials in Asia-Pacific populations.